Weekly reads: CBER changes, Parkinson’s, 2-dad mice, NIH woes continue
I recently looked at the organizational chart at the FDA’s Center for Biologics Evaluation and Research or CBER. Why? I have been anticipating some possible big changes there with the new administration. After all, with HHS Secretary RFK Jr. having previously claimed that the FDA was suppressing various unproven things including at least two kinds […]
Weekly reads: CBER changes, Parkinson’s, 2-dad mice, NIH woes continue Read More »